A markerless 2D video of facial features recognition based artificial intelligence model to assist Parkinson’s disease diagnosis (Preprint)

2021 ◽  
Author(s):  
Yu Zhang

UNSTRUCTURED Background: Mask face is a characteristic clinical manifestation of Parkinson's disease (PD), but subjective evaluations from different clinicians often show low consistency owing to lacking accurate detection technology. With the objective of making monitoring easier and more accessible, we developed a markerless 2D video of facial features recognition based artificial intelligence (AI) model to assess facial features of PD patients and aimed to investigate how AI could help neurologists improve PD early diagnostic performance. Methods: We collected 140 videos of facial expressions of 70 PD patients and 70 healthy controls from three hospitals. We developed and tested the AI model that performs mask face recognition of PD patients based on the acquisition and evaluation of facial features including geometric features and texture features, using a single 2D video camera. The diagnostic performance of AI model was compared with 5 neurologists. Results: Experimental results show that our AI models can achieve feasible and effective facial feature recognition ability to assist PD diagnosis. The precision and F1 values of PD diagnosis can reach 83% and 86%, using geometric features and texture features, respectively. When these two features are combined, a F1 value of 88% can be reached. Further, the facial features of patients with PD were not affected by the motor and non-motor symptoms of PD. Conclusions: PD patients commonly exhibit facial features. Video of facial features recognition based AI model can provide a valuable tool to assist PD diagnosis and potential of realizing remote monitoring on patients’ condition especially on the COVID-19 pandemic.

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S16-S17
Author(s):  
Connie Marras ◽  
Laura C Maclagan ◽  
Yi Cheng ◽  
Naomi Visanji ◽  
Mina Tadrous ◽  
...  

Abstract Given the high cost of drug development and low success rates, repurposing drugs already proven safe provides a promising avenue for identifying effective therapies with additional indications. The IBM Watson artificial intelligence system was used to search 1.3 million Medline abstracts to prioritize medications that may be potentially disease-modifying in Parkinson’s disease. We assessed patterns of use of the top 50 Watson-ranked drugs among 14,866 adults with Parkinson’s disease aged 70 and older who were matched to persons without Parkinson’s disease on age, sex, and comorbidity. Sociodemographic characteristics, chronic conditions, and use of other medications were compared using standardized differences. Patterns of potentially disease-modifying drug use were examined prior to and following ascertainment of Parkinson’s disease. Preliminary findings from multivariable conditional logistic regression models on the association between previous exposure to potentially disease-modifying drugs and Parkinson’s disease diagnosis will be presented.


Author(s):  
Yareth Gopar-Cuevas ◽  
Ana P. Duarte-Jurado ◽  
Rosa N. Diaz-Perez ◽  
Odila Saucedo-Cardenas ◽  
Maria J. Loera-Arias ◽  
...  

Metabolites ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 14
Author(s):  
Petr G. Lokhov ◽  
Dmitry L. Maslov ◽  
Steven Lichtenberg ◽  
Oxana P. Trifonova ◽  
Elena E. Balashova

A laboratory-developed test (LDT) is a type of in vitro diagnostic test that is developed and used within a single laboratory. The holistic metabolomic LDT integrating the currently available data on human metabolic pathways, changes in the concentrations of low-molecular-weight compounds in the human blood during diseases and other conditions, and their prevalent location in the body was developed. That is, the LDT uses all of the accumulated metabolic data relevant for disease diagnosis and high-resolution mass spectrometry with data processing by in-house software. In this study, the LDT was applied to diagnose early-stage Parkinson’s disease (PD), which currently lacks available laboratory tests. The use of the LDT for blood plasma samples confirmed its ability for such diagnostics with 73% accuracy. The diagnosis was based on relevant data, such as the detection of overrepresented metabolite sets associated with PD and other neurodegenerative diseases. Additionally, the ability of the LDT to detect normal composition of low-molecular-weight compounds in blood was demonstrated, thus providing a definition of healthy at the molecular level. This LDT approach as a screening tool can be used for the further widespread testing for other diseases, since ‘omics’ tests, to which the metabolomic LDT belongs, cover a variety of them.


2021 ◽  
pp. 1-6
Author(s):  
Matt Landers ◽  
Suchi Saria ◽  
Alberto J. Espay

The use of artificial intelligence (AI) to help diagnose and manage disease is of increasing interest to researchers and clinicians. Volumes of health data are generated from smartphones and ubiquitous inexpensive sensors. By using these data, AI can offer otherwise unobtainable insights about disease burden and patient status in a free-living environment. Moreover, from clinical datasets AI can improve patient symptom monitoring and global epidemiologic efforts. While these applications are exciting, it is necessary to examine both the utility and limitations of these novel analytic methods. The most promising uses of AI remain aspirational. For example, defining the molecular subtypes of Parkinson’s disease will be assisted by future applications of AI to relevant datasets. This will allow clinicians to match patients to molecular therapies and will thus help launch precision medicine. Until AI proves its potential in pushing the frontier of precision medicine, its utility will primarily remain in individualized monitoring, complementing but not replacing movement disorders specialists.


2021 ◽  
Author(s):  
Shengfang Song ◽  
Zhehui Luo ◽  
Chenxi Li ◽  
Xuemei Huang ◽  
Eric J. Shiroma ◽  
...  

2021 ◽  
pp. 132368
Author(s):  
Jiapei Yang ◽  
Lei Wang ◽  
Yue Su ◽  
Lingyue Shen ◽  
Xihui Gao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document